医学
半影
溶栓
血运重建
纸牌密码算法
冲程(发动机)
间隙
缺血性中风
急性中风
外科
心脏病学
组织纤溶酶原激活剂
内科学
缺血
改良兰金量表
心肌梗塞
工程类
泌尿科
机械工程
作者
Juyu Chueh,Anna Luisa Kühn,Ajit S Puri,Ajay K. Wakhloo,Matthew J. Gounis
出处
期刊:Volume 1A: Abdominal Aortic Aneurysms; Active and Reactive Soft Matter; Atherosclerosis; BioFluid Mechanics; Education; Biotransport Phenomena; Bone, Joint and Spine Mechanics; Brain Injury; Cardiac Mechanics; Cardiovascular Devices, Fluids and Imaging; Cartilage and Disc Mechanics; Cell and Tissue Engineering; Cerebral Aneurysms; Computational Biofluid Dynamics; Device Design, Human Dynamics, and Rehabilitation; Drug Delivery and Disease Treatment; Engineered Cellular Environments
日期:2013-06-26
标识
DOI:10.1115/sbc2013-14634
摘要
Expedited revascularization through pharmacologic dissolution and/or mechanical thrombectomy is the principle goal of treatment of ischemic stroke [1]. Pharmacologic therapy consists of intravenous thrombolysis with tissue plasminogen activator and is limited by a narrow time window within which to administer the medication, resulting in less than 10% utilization in stroke patients. Mechanical thrombectomy provides another option for flow recanalization. Four thrombectomy devices are cleared by the FDA to restore blood flow in ischemic stroke patients, namely, the Merci retriever, the Penumbra aspiration system, the Solitaire FR revascularization device, and the Trevo device. While several completed and ongoing clinical trials have shown enhancement in the design of thrombectomy devices and increase in recanalization rate [2–4], the recanalization rate and, more importantly, the clinical outcome achieved with current thrombectomy devices still remain to be optimized.
科研通智能强力驱动
Strongly Powered by AbleSci AI